Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FOLH1 | Q04609 | 4/20 | 0.42 |
| ▸ | LTA4H | P09960 | 1/20 | 0.41 |
| ▸ | SLC1A3 | P43003 | 1/20 | 0.41 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.41 |
| ▸ | EPOR | P19235 | 3/20 | 0.41 |
| ▸ | DPP8 | Q6V1X1 | 2/20 | 0.41 |
| ▸ | DPP7 | Q9UHL4 | 2/20 | 0.41 |
| ▸ | CPB1 | P15086 | 1/20 | 0.40 |
| ▸ | CPB2 | Q96IY4 | 1/20 | 0.40 |
| ▸ | MMP2 | P08253 | 1/20 | 0.40 |
| ▸ | ANPEP | P15144 | 1/20 | 0.40 |
| ▸ | TPSAB1 | Q15661 | 2/20 | 0.39 |
| ▸ | TPSD1 | Q9BZJ3 | 2/20 | 0.39 |
| ▸ | TPSG1 | Q9NRR2 | 2/20 | 0.39 |
| ▸ | DPP4 | P27487 | 1/20 | 0.39 |
| ▸ | DPP9 | Q86TI2 | 1/20 | 0.39 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.38 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.38 |
| ▸ | SIRT3 | Q9NTG7 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27892485 | 0.88 | NPY4R (0.42) | FOLH1LTA4HSLC1A3SLC1A1EPOR | |
| SCHEMBL9128839 | 0.87 | LTA4H (0.40) | LTA4HSLC1A3SLC1A1EPORDPP8 | |
| SCHEMBL2030161 | 0.87 | FOLH1 (0.47) | FOLH1SLC1A3SLC1A1DPP8DPP7 | |
| SCHEMBL2030163 | 0.87 | FOLH1 (0.47) | FOLH1SLC1A3SLC1A1DPP8DPP7 | |
| SCHEMBL29766659 | 0.86 | DPP8 (0.43) | FOLH1SLC1A3SLC1A1DPP8DPP7 | |
| SCHEMBL29266083 | 0.85 | FOLH1 (0.46) | FOLH1SLC1A3SLC1A1EPORDPP8 | |
| SCHEMBL8699994 | 0.84 | MMP2 (0.51) | FOLH1LTA4HSLC1A3SLC1A1EPOR | |
| SCHEMBL9314043 | 0.82 | DPP8 (0.41) | SLC1A3SLC1A1DPP8DPP7ANPEP | |
| SCHEMBL7358353 | 0.81 | DPP8 (0.40) | SLC1A3SLC1A1DPP8DPP7ANPEP | |
| SCHEMBL27913200 | 0.81 | ANPEP (0.43) | LTA4HMMP2ANPEP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4743437-A1 | DIESTER LIPIDS, LIPID NANOPARTICLE CONTAINING DIESTER LIPIDS, AND FORMULATIONS THEREOF | Providence Therapeutics Holdings Inc. (CA) | 2026-05-20 | — | — | EP | disclosed |
| EP-4731258-A1 | LIPID NANOPARTICLES CONTAINING DISULFIDE LIPIDS AND FORMULATIONS THEREOF | Providence Therapeutics Holdings Inc. (CA) | 2026-04-29 | — | — | EP | disclosed |
| WO-2025076625-A1 | GLUTAMIC ACID-BASED LIPIDS, LIPID NANOPARTICLE CONTAINING GLUTAMIC ACID-BASED LIPIDS, AND FORMULATIONS THEREOF | PROVIDENCE THERAPEUTICS HOLDINGS INC. (CA) | 2025-04-17 | — | — | WO | disclosed |
| EP-4522757-A2 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF HER2 POSITIVE CANCER | Voyager Therapeutics, Inc. (US) | 2025-03-19 | — | — | EP | disclosed |
| WO-2025010504-A1 | DIESTER LIPIDS, LIPID NANOPARTICLE CONTAINING DIESTER LIPIDS, AND FORMULATIONS THEREOF | PROVIDENCE THERAPEUTICS HOLDINGS INC. (CA) | 2025-01-16 | — | — | WO | disclosed |
| WO-2025015060-A1 | ENGINEERED VECTORIZED ANTIBODIES WITH REDUCED STABILITY IN SYSTEMIC CIRCULATION AND USES THEREOF | BRAVE BIO, INC. (US) | 2025-01-16 | — | — | WO | disclosed |
| WO-2024259531-A1 | LIPID NANOPARTICLES CONTAINING DISULFIDE LIPIDS AND FORMULATIONS THEREOF | PROVIDENCE THERAPEUTICS HOLDINGS INC. (CA) | 2024-12-26 | — | — | WO | disclosed |
| EP-4405396-A2 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF HER2 POSITIVE CANCER | Voyager Therapeutics, Inc. (US) | 2024-07-31 | — | — | EP | disclosed |
| EP-4402121-A1 | ACYCLIC LIPIDS AND METHODS OF USE THEREOF | Renagade Therapeutics Management Inc. (US) | 2024-07-24 | — | — | EP | disclosed |
| WO-2023220695-A2 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF HER2 POSITIVE CANCER | VOYAGER THERAPEUTICS, INC. (US) | 2023-11-16 | — | — | WO | disclosed |
| WO-2023086379-A2 | COMPOSITIONS AND METHODS FOR TCR REPROGRAMMING USING FUSION PROTEINS | TCR2 Therapeutics Inc. (US) | 2023-05-19 | — | — | WO | disclosed |
| WO-2023044343-A1 | ACYCLIC LIPIDS AND METHODS OF USE THEREOF | RENAGADE THERAPEUTICS MANAGEMENT INC. (US) | 2023-03-23 | — | — | WO | disclosed |
| WO-2023044483-A2 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF HER2 POSITIVE CANCER | VOYAGER THERAPEUTICS, INC. (US) | 2023-03-23 | — | — | WO | disclosed |
| WO-2023014633-A2 | VECTOR SYSTEMS FOR DELIVERY OF TWO POLYNUCLEOTIDES AND METHODS OF MAKING AND USING SAME | A2 BIOTHERAPEUTICS, INC. (US) | 2023-02-09 | — | — | WO | disclosed |
| EP-3966227-A1 | COMPOSITIONS AND METHODS FOR THE VECTORED AUGMENTATION OF PROTEIN DESTRUCTION, EXPRESSION AND/OR REGULATION | Voyager Therapeutics, Inc. (US) | 2022-03-16 | — | — | EP | disclosed |